TN2013000246A1 - Use of chimeric antigen receptor-modified t cells to treat cancer - Google Patents

Use of chimeric antigen receptor-modified t cells to treat cancer

Info

Publication number
TN2013000246A1
TN2013000246A1 TNP2013000246A TN2013000246A TN2013000246A1 TN 2013000246 A1 TN2013000246 A1 TN 2013000246A1 TN P2013000246 A TNP2013000246 A TN P2013000246A TN 2013000246 A TN2013000246 A TN 2013000246A TN 2013000246 A1 TN2013000246 A1 TN 2013000246A1
Authority
TN
Tunisia
Prior art keywords
modified
cells
antigen receptor
chimeric antigen
treat cancer
Prior art date
Application number
TNP2013000246A
Other languages
French (fr)
Inventor
Carl H June
Bruce L Levine
David L Porter
Michael D Kalos
Michael C Milone
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/064191 external-priority patent/WO2012079000A1/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of TN2013000246A1 publication Critical patent/TN2013000246A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Abstract

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
TNP2013000246A 2011-06-29 2013-06-07 Use of chimeric antigen receptor-modified t cells to treat cancer TN2013000246A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502649P 2011-06-29 2011-06-29
PCT/US2011/064191 WO2012079000A1 (en) 2010-12-09 2011-12-09 Use of chimeric antigen receptor-modified t cells to treat cancer

Publications (1)

Publication Number Publication Date
TN2013000246A1 true TN2013000246A1 (en) 2014-11-10

Family

ID=52395350

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000246A TN2013000246A1 (en) 2011-06-29 2013-06-07 Use of chimeric antigen receptor-modified t cells to treat cancer

Country Status (3)

Country Link
CU (1) CU20130079A7 (en)
EA (1) EA202090716A1 (en)
TN (1) TN2013000246A1 (en)

Also Published As

Publication number Publication date
CU20130079A7 (en) 2013-09-27
EA202090716A1 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
MX2020005143A (en) Use of chimeric antigen receptor-modified t cells to treat cancer.
MX2018009820A (en) Use of cart19 to deplete normal b cells to induce tolerance.
IN2014DN06522A (en)
WO2013040557A3 (en) Rna engineered t cells for the treatment of cancer
MX2020007021A (en) Treatment of cancer using humanized anti-cd19 chimeric antigen receptor.
IN2014DN07414A (en)
IN2014DN11155A (en)
MX2018005618A (en) Chimeric receptors containing traf-inducing domains and related compositions and methods.
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014055442A3 (en) Compositions and methods for targeting stromal cells for the treatment of cancer
MX2017001008A (en) Treatment of cancer using a cd33 chimeric antigen receptor.
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
MX2014010183A (en) Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer.
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
MX347164B (en) Anti il-36r antibodies.
MX2013008376A (en) Compositions and methods for treating cancer.
WO2014011988A3 (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
MX2014004326A (en) ANTIBODIES TO CD1d.
TN2013000246A1 (en) Use of chimeric antigen receptor-modified t cells to treat cancer